AngioDynamics (NASDAQ:ANGO) SVP Sells 23,370 Shares of Stock

AngioDynamics, Inc. (NASDAQ:ANGO) SVP Warren Nighan, Jr. sold 23,370 shares of the company’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

AngioDynamics Price Performance

Shares of ANGO stock traded up $0.02 during midday trading on Friday, hitting $14.79. The company had a trading volume of 467,477 shares, compared to its average volume of 482,654. The stock has a market cap of $611.30 million, a price-to-earnings ratio of -17.00 and a beta of 0.34. The company’s 50 day simple moving average is $12.75 and its 200 day simple moving average is $11.48. AngioDynamics, Inc. has a 52-week low of $8.36 and a 52-week high of $15.19.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The business had revenue of $86.61 million during the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Analysts anticipate that AngioDynamics, Inc. will post -0.27 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on ANGO shares. HC Wainwright upped their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Canaccord Genuity Group lifted their price objective on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Freedom Capital raised AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Finally, Zacks Research cut AngioDynamics from a “hold” rating to a “strong sell” rating in a report on Thursday, July 16th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $19.50.

Institutional Trading of AngioDynamics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC grew its position in AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 1,199 shares during the period. Kemnay Advisory Services Inc. purchased a new position in AngioDynamics in the fourth quarter valued at about $27,000. State of Wyoming acquired a new stake in shares of AngioDynamics during the 2nd quarter valued at approximately $31,000. Russell Investments Group Ltd. boosted its stake in shares of AngioDynamics by 329.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 3,213 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of AngioDynamics by 359.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier’s stock worth $54,000 after acquiring an additional 4,268 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.